Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment

NCT06361823 on ClinicalTrials.gov · last registry update 2024-04-12

A small phase 3 — 74 participants, against a typical 424. Its estimated completion date, 1 December 2024, has passed with no update to the record. Primary outcome, as filed: Intracranial pressure. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is approved in the US, but not for hypertension — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: UNKNOWN
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Capital Medical University
Sponsor type: Other
Enrollment: 74
Started: 2024-05-01
Primary completion: 2024-12-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Intracranial pressure

Conditions studied

Idiopathic Intracranial Hypertension

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.